Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus + mycophenolate mofetil + anti-thymocyte globulin + anakinra
- Development stage
- Unknown
- Lead developer
- IRCCS Ospedale San Raffaele
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This CNI-free immunosuppressive regimen was developed by Ospedale San Raffaele specifically for patients with type 1 diabetes mellitus undergoing pancreatic islet transplantation. The protocol aims to replace standard calcineurin inhibitors (CNIs), which can be nephrotoxic and detrimental to islet cell function, with a combination of sirolimus (an mTOR inhibitor), mycophenolate mofetil (an antimetabolite), anti-thymocyte globulin (ATG, for T-cell depletion), and anakinra (an IL-1 receptor antagonist). This specific combination is designed to create a permissive environment for islet graft survival and the potential expansion of regulatory T cells (Tr1 cells) to promote immune tolerance. The regimen includes an induction phase with ATG and anakinra, followed by maintenance therapy with sirolimus and mycophenolate mofetil.
- Other names
- CNI-free immunosuppression (Ospedale San Raffaele)CNI-free immunosuppressive regimen (San Raffaele)Rapamycin + MMF + ATG + Anakinra
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on sirolimus + mycophenolate mofetil + anti-thymocyte globulin + anakinra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus + mycophenolate mofetil + anti-thymocyte globulin + anakinra.